A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Fadi Saab, MD, FACC, FSCAI; Mahmood Razavi, MD; Lucas Ferrer Cardona, MD; Miguel Montero-Baker, MD; Dean Ferrera, DO; Stylianos Papadakos, MD
Watch the Amputation Prevention Symposium session as an expert panel of physicians present cases and discuss their experiences capturing acute or chronic clot in ATK and BTK peripheral arteries with the Pounce™ Thrombectomy Platform.
Watch the Amputation Prevention Symposium session as an expert panel of physicians present cases and discuss their experiences capturing acute or chronic clot in ATK and BTK peripheral arteries with the Pounce™ Thrombectomy Platform.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
The live online symposium will be held September 26-27, 2025. While radiation protection is discussed at other conferences, SIRP is the first program dedicated entirely to radiation safety with a goal of reducing the number of...
The live online symposium will be held September 26-27, 2025. While radiation protection is discussed at other conferences, SIRP is the first program dedicated entirely to radiation safety with a goal of reducing the number of...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
May 5, 2026 – Cambridge, UK – Upfront Diagnostics today announced the commercial launch of LVOne, a rapid blood test designed to help identify large vessel occlusion (LVO) strokes in the pre-hospital setting. The test has received UKCA...
May 5, 2026 – Cambridge, UK – Upfront Diagnostics today announced the commercial launch of LVOne, a rapid blood test designed to help identify large vessel occlusion (LVO) strokes in the pre-hospital setting. The test has received UKCA...
Landmark Milestone Reached in Single-Arm Study Evaluating the BASHIR® Endovascular System for Pulmonary Embolism Treatment
New Britain, PA, April 30, 2026 — Thrombolex, Inc., a medical device company dedicated to advancing minimally...
Landmark Milestone Reached in Single-Arm Study Evaluating the BASHIR® Endovascular System for Pulmonary Embolism Treatment
New Britain, PA, April 30, 2026 — Thrombolex, Inc., a medical device company dedicated to advancing minimally...
The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention through three years.(2)
The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention through three years.(2)
Serration Remodeling Therapy (SRT) is a novel approach to optimizing luminal gain by gently remodeling the internal elastic lamina through creating a line of weakness to reduce recoil and support durable outcomes.
Serration Remodeling Therapy (SRT) is a novel approach to optimizing luminal gain by gently remodeling the internal elastic lamina through creating a line of weakness to reduce recoil and support durable outcomes.
Preliminary 3-Year SIRONA Data Presented at CX-2026 Demonstrate Durable Freedom from Reintervention with MagicTouch PTA in Femoropopliteal Disease
London, 21 April 2026: Concept Medical Inc., today announced the presentation of preliminary...
Preliminary 3-Year SIRONA Data Presented at CX-2026 Demonstrate Durable Freedom from Reintervention with MagicTouch PTA in Femoropopliteal Disease
London, 21 April 2026: Concept Medical Inc., today announced the presentation of preliminary...
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1
Medtronic, a global leader in healthcare technology, today announced...
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1
Medtronic, a global leader in healthcare technology, today announced...
